GlassScriptPhysician profile
Patrick J Hobbins
NPI 1518134816
$1,600.81
in general payments reported to CMS, 2019-2025
28 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $17.78 · 2021: $210 · 2022: $267 · 2023: $271 · 2024: $156 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.59 | 2021-2025 | |
| Amgen INC. | $215.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $181.44 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $108.35 | 2019-2024 | Wegovy |
| Corium, LLC | $100.42 | 2021-2023 | Azstarys |
| Lilly USA, LLC | $93.83 | 2021-2024 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $83.21 | 2023-2025 | Quviviq, Quviviq |
| Pfizer INC. | $56.23 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $54.17 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $52.86 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $40.54 | 2019-2020 | |
| Astellas Pharma US INC | $38.24 | 2019 | |
| Glaxosmithkline, LLC. | $29.94 | 2019-2023 | Nucala |
| Allergan, INC. | $28.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.38 | 2019-2024 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.01 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2022 | |
| Madrigal Pharmaceuticals | $19.98 | 2025 | Rezdiffra |
| Biohaven Pharmaceuticals, INC. | $18.83 | 2021 | |
| Shire North American Group INC | $18.62 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.45 | 2022 | |
| Halozyme INC | $17.16 | 2023 | |
| Adlon Therapeutics L.P. | $15.68 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.96 | 2023 | Edarbi |
| Genentech USA, INC. | $14.10 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.98 | 2019 | |
| Merck Sharp & Dohme LLC | $11.93 | 2019 | |
| Ethicon US, LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hobbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.